Comment

  • 8 June 2018

    ASCO 2018: is LAG-3 the next checkpoint target?

    On June 4 at this year’s American Society of Clinical Oncology (ASCO) annual meeting, Novartis reported dose escalation results from its Phase I/II study of anti-LAG-3 monoclonal antibody LAG525 with...

Close
Close
Close

Go Top